Congenital rubella syndrome after rubella vaccination in 1-4 weeks periconceptional period.
OBJECTIVE
To examine weather exposure to rubella vaccine during 1-4 wk periconceptional period can cause congenital rubella syndrome (CRS).


METHODS
This prospective study was performed in 60 pregnant women who received rubella vaccine inadvertently 1-4 wk pre or post conception. Time of conception was determined by last menstrual period (LMP) and first trimester sonography. In addition to gathering mother's obstetric and demographic information, all neonates were evaluated for CRS signs by systemic physical examination and anti rubella IgG and IgM antibody titers in cord blood samples.


RESULTS
A total of 60 pregnant women with the median gestational age of 38 weeks were studied. The mean maternal age was 22 years and 58.3% of pregnancies were unintended. In 90% of mothers there were no post vaccination side effects (fever, lymphadenopathy, arthritis, arthralgia). None of the mothers had a history of drug abuse, smoking or teratogenic exposures. Mean neonatal weight was 3100grs and 6.7% of them were premature. No signs of CRS were found in the neonates based on systemic physical exam at birth and one month later. Mean value of cord blood anti rubella IgG titere was 148/28+/-67/26 lu/ml. cord blood anti rubella IgM was negative in all of the neonates.


CONCLUSIONS
In this study inadvertent rubella vaccination 1-4 wk before and after conception did not cause CRS in neonates and according to all reasearches pregnancy termination is not indicated in these cases.
Nasiri
R
R
Department of Obstetrics and Gynecology, Bahman Hospital, Islamic Azad University, Mashhad, Khorasan, Iran. nasiri.roya@mshdiau.ac.ir
Yoseffi
J
J
Khajedaloe
M
M
Sarafraz Yazdi
M
M
Delgoshaei
F
F
D000328:Adult; D000888:Antibodies, Anti-Idiotypic; D005260:Female; D005306:Fertilization / Q000502:physiology; D005312:Fetal Blood / Q000276:immunology*; D005865:Gestational Age; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007231:Infant, Newborn; D007492:Iran / Q000453:epidemiology; D016742:Preconception Care; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology / Q000517:prevention & control; D011256:Pregnancy Outcome; D011446:Prospective Studies; D012307:Risk Factors; D012410:Rubella Syndrome, Congenital / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D012411:Rubella Vaccine / Q000009:adverse effects* / Q000276:immunology; D014611:Vaccination
D000888:Antibodies, Anti-Idiotypic; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D012411:Rubella Vaccine; C048844:anti-IgG; C044203:anti-IgM